Is There a Role for MRD-Response Adapted Therapy in Transplant-Eligible NDMM?

Video

Dr Ajay Nooka describes key data from the uniquely-designed MASTER trial investigating daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (Dara-KRd) versus KRd in transplant-eligible newly diagnosed multiple myeloma.

Related Videos
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
Craig Cole, MD, an expert on multiple myeloma, presenting slides
Experts on MM
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
Related Content